ZEUS: Trial to Evaluate Reduction in Inflammation in Patients with Advanced Chronic Renal Disease
The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to a placebo (an inactive substance) in reducing inflammation and improving some of the bad effects of inflammation on heart disease. Participants will be randomly (by chance) assigned to receive either ziltivekimab or placebo. The chance that participants will be assigned into one of the three study arms of ziltivekimab (either 15 mg or 30 mg) or placebo is the same (approximately 33%). The study drug will be injected under the skin once every 4 weeks. In this study, participants will receive 3 injections of study drug. The total study duration for each participant will be approximately 6 months.
- Age equal to or above 20 years at the time of signing the Informed Consent Form
- Stage 3 to 5 non-dialysis-dependent chronic kidney disease
- Patients with a history of advanced-stage CKD, atherosclerotic cardiovascular disease, anemia, diabetic retinopathy, obesity, or elevated BMI, and diabetes